We first looked at genome-wide changes induced by OTX015 and found that the changes seen in our ALCL cell lines displayed a high degree of overlap with the signatures previously reported in B-cell lymphomas treated with the same compound [22] (Figure 4A) or with the BET inhibitor JQ1 in other hematologic malignancy models (Figure 4B–4C) [20, 44]. Here, DNER is linked to B-cell non-Hodgkin lymphoma.